Dermatology · Stuart, FL
NPI
1144303009
Since 2006
Specialty
Dermatology
Code 207N00000X
Group practices
2
Medicare group memberships
Hospitals
2
Hospital affiliations
2601 S Kanner Hwy
Stuart, FL, 34994
Phone (772) 219-2777
Groups this clinician bills Medicare through
Medicare paid, 2024
$638K
17,495 services
Medicare patients, 2024
3,260
Average age 75
Drug cost, 2024
$5.1M
8,437 prescriptions
Company payments, 2025
$328K
From 19 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by John P Minni was code 17003 (destruction skin lesion), 7,444 times for 1,345 patients. In total John P Minni billed 17,495 services in 43 codes, and Medicare paid $638K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-01-05.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 17003 Destruction Skin Lesion | Office | 7,444 | 1,345 | $4.81 | $36K |
| 99213 Office E&M - Established | Office | 3,025 | 2,273 | $59.42 | $180K |
| 17000 Destruction Skin Lesion | Office | 2,539 | 1,845 | $37.99 | $96K |
| 17110 Destruction Skin Lesion | Office | 1,240 | 1,029 | $77.51 | $96K |
| 99214 Office E&M - Established | Office | 1,082 | 812 | $85.98 | $93K |
| 11102 Skin Biopsy | Office | 642 | 584 | $63.15 | $41K |
| 99212 Office E&M - Established | Office | 306 | 289 | $37.77 | $12K |
| 99203 Office E&M - New | Office | 293 | 293 | $61.10 | $18K |
| 17004 Destruction Skin Lesion | Office | 196 | 162 | $118.40 | $23K |
| 99204 Office E&M - New | Office | 108 | 108 | $101.82 | $11K |
| 96372 Injection Administration | Office | 104 | 40 | $10.18 | $1,058 |
| 11103 Skin Biopsy | Office | 95 | 74 | $39.45 | $3,747 |
| 17111 Destruction Skin Lesion | Office | 61 | 52 | $88.84 | $5,419 |
| J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 44 | 31 | $0.76 | $33.61 |
| 11200 Removal or Shaving of Skin Growth | Office | 40 | 39 | $51.25 | $2,050 |
By year: 2022 $654K for 17,748 services; 2023 $629K for 17,263 services; 2024 $638K for 17,495 services.
Medicare prescription drug claims, 2024
In 2024, the drug John P Minni prescribed most often to Medicare patients was Clobetasol Propionate, with 946 prescriptions and refills. In total John P Minni wrote 8,437 Medicare prescriptions that cost $5.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Clobetasol Propionate Generic | 946 | 994 | 646 | $38K |
| Minoxidil Generic | 840 | 2,024 | 305 | $11K |
| Ketoconazole Generic | 558 | 624 | 316 | $8,233 |
| Triamcinolone Acetonide Generic | 553 | 594 | 396 | $4,949 |
| Doxycycline Hyclate Generic | 490 | 695 | 155 | $14K |
| Mupirocin Generic | 459 | 470 | 317 | $4,367 |
| Mometasone Furoate Generic | 346 | 366 | 243 | $6,271 |
| Fluorouracil Generic | 338 | 352 | 299 | $19K |
| Ciclopirox Ciclopirox Olamine | 333 | 403 | 203 | $8,185 |
| Prednisone Generic | 239 | 252 | 172 | $1,242 |
| Finasteride Generic | 215 | 567 | 101 | $2,495 |
| Clindamycin Phosphate Generic | 210 | 237 | 157 | $4,346 |
| Valacyclovir Valacyclovir Hcl | 164 | 182 | 64 | $3,503 |
| Nystatin Generic | 160 | 184 | 96 | $2,065 |
| Dupixent Pen Dupilumab | 151 | 156 | 23 | $597K |
Brand drugs: 750 claims; generic drugs: 7,687 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid John P Minni $328K ($328K in general payments such as food, travel and fees) from 19 companies. The largest payer was UCB, Inc. with $91K.
| Company | Payments | Amount |
|---|---|---|
| UCB, Inc. UCB.BR | 96 | $91K |
| Janssen Biotech, Inc. JNJ | 74 | $68K |
| Regeneron Healthcare Solutions, Inc. REGN | 35 | $36K |
| Organon LLC OGN | 38 | $27K |
| Galderma Laboratories, L.P. GALD.SW | 42 | $22K |
| Incyte Corporation INCY | 30 | $19K |
| Abbvie Inc. ABBV | 40 | $15K |
| Amgen Inc. AMGN | 18 | $12K |
| Genzyme Corporation SNY | 13 | $12K |
| Lilly USA, LLC LLY | 16 | $10K |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.